Prevention of breast cancer

Critical Reviews in Oncology/Hematology

Volumn 33, Issue 3, 2000, Pages 221-238

  Carolin, Kathryn A ^a   Pass, Helen A ^a  

^a UNIVERSITY OF MICHIGAN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BIOLOGICAL MARKER; CAROTENOID; LYSOSOME ENZYME; NONSTEROID ANTIINFLAMMATORY AGENT; RETINOID; SELENIUM; TAMOXIFEN; TERPENE;

ANGIOGENESIS; ANIMAL MODEL; BREAST CANCER; CANCER INCIDENCE; CANCER PREVENTION; CANCER RISK; CANCER SCREENING; CELL ADHESION; CELL CYCLE; CHEMOPROPHYLAXIS; CLINICAL TRIAL; GAP JUNCTION; HIGH RISK PATIENT; HUMAN; MALIGNANT TRANSFORMATION; MASTECTOMY; NONHUMAN; OVARIECTOMY; REVIEW; RISK FACTOR;

ADULT; AGED; ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTICARCINOGENIC AGENTS; APOPTOSIS; BIOLOGICAL PRODUCTS; BREAST NEOPLASMS; BREAST NEOPLASMS, MALE; CAROTENOIDS; CATHEPSIN D; CELL ADHESION MOLECULES; CELL CYCLE; CLINICAL TRIALS, PHASE III; DRUG SCREENING ASSAYS, ANTITUMOR; ESTROGENS, NON-STEROIDAL; FEMALE; FENRETINIDE; GENETIC PREDISPOSITION TO DISEASE; HORMONE ANTAGONISTS; HUMANS; ISOFLAVONES; MALE; MAMMARY NEOPLASMS, EXPERIMENTAL; MASTECTOMY; MICE; MIDDLE AGED; NEOVASCULARIZATION, PATHOLOGIC; OVARIECTOMY; PHYTOESTROGENS; PLANT PREPARATIONS; RALOXIFENE; RATS; RETINOIDS; RISK ASSESSMENT; RISK FACTORS; SELENIUM; TAMOXIFEN; TERPENES;

EID: 0034102595     PISSN: 10408428     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1040-8428(99)00076-1     Document Type: Article

References (162)

1. Chang J.C. A review of breast cancer chemoprevention. Biomed. Pharmacother. 52:1998;133-136.
2. Parker S.L., Tong T., Bolder S., Wingo P.A. Cancer Statistics, 1998. CA Cancer J. Clin. 48:1998;6-29.
3. Feuer E.J., Wun L.M., Boring C.C. et al. The lifetime risk of developing breast cancer. J. Natl. Cancer Inst. 85(11):1993;892-897.
4. Garber J.E., Smith B.L. Management of the high-risk and the concerned patient. Harris J.R., Lippman M.E., Morrow M., Hellman S. Diseases of the Breast. 1996;323-334 Lippincott-Raven Publishers, Philadelphia.
5. Lerman C., Croyle R. Psychological issues in genetic testing for breast cancer susceptibility. Arch. Intern. Med. 154:1994;609.
6. Lerman C., Daly M., Sands C. et al. Mammography adherence and psychological distress among women at risk for breast cancer. J. Natl. Cancer Inst. 85:1993;1074.
7. Ottman R., Pike M.C., King M.C. Practical guide for estimating risk for familial breast cancer. Lancet. 2:1983;556-558.
8. Seidman H., Mushinski M., Gelb S. et al. Probabilities of eventually developing or dying of cancer. United States, 1985. CA Cancer J. Clin. 35(1):1985;37-57.
9. Claus E.B., Gail M.H., Brinton L.A., Byar D.P. et al. Projecting individualized probabilities of developing breast cancer for white females who are being examined annually. J. Natl. Cancer Inst. 81(24):1989;1879-1886.
10. Offit K., Brown K. Quantitating familial cancer risk: a resource for clinical oncologist. J. Clin. Oncol. 12(8):1994;1724-1736.
11. Gail M.H., Benichou J. Epidemiology and biostatistics of the National Cancer Institute. J. Natl. Cancer Inst. 86(8):1994;573-575.
12. Benichou J., Gail M.H., Mulvihill J.J. Graphs to estimate an individualized risk of breast cancer. J Clin Oncol. 14(1):1996;103-110.
13. Bondy M., Lustbader E., Halabi S. et al. Validation of a breast cancer risk assessment model in women with a positive family history. J. Natl. Cancer Inst. 86(8):1994;620-625.
14. Speigelman D., Colditz G.A., Hunter D. et al. Validation of the Gail et al. model for predicting individual breast cancer risk. J. Natl. Cancer Inst. 86(8):1994;600-607.
15. Clause E.B., Risch N., Thompson W.D. The calculation of breast cancer risk for women with a first degree family history of ovarian cancer. Breast Cancer Res. Treat. 28:1993;115-120.
16. Anderson D.E., Badzioch M.D. Risk of familial breast cancer. Cancer. 56:1985;383-387.
17. Wingo P.A., Ory H.W., Layde P.M. et al. The evaluation of the data collection process for a multicenter, population-based, case-control design. Am. J. Epidemiol. 128:1988;206-217.
18. Claus E.B., Risch N.J., Thompson W.D. Age at onset as an indicator of familial risk of breast cancer. Am. J. Epidemiol. 131:1990;961-972.
19. Claus E.B., Risch N.J., Thompson W.D. Autosomal dominant inheritance of early-onset breast cancer. Cancer. 73(3):1994;643-651.
20. Couch F.J., DeShano M.L., Blackwook M.A., Calzone K., Stopfer J., Campeau L., Ganguly A., Rebbeck T., Weber B.L. BRCA1 mutations in women attending clinics that evaluate the risk of breast cancer. N. Engl. J. Med. 336:1997;1409-1415.
21. Parmigiani G., Berry D., Aguilar O. Determing carrier probabilities for breast cancer-susceptibility genes BRCA1 and BRCA2. Am. J. Hum. Genet. 62(1):1998;145-158.
22. Ahearne P.M., Leach S.C., Feig B.W. Invasive breast cancer. Feig B.W., Berger D.H., Fuhrman G.M. The MD Anderson Surgical Oncology Handbook. 2nd ed:1999;13-37 Lippincott Williams &Wilkins, Philadelphia.
23. Henderson B.E., Bernstein L. Endogenous and exogenous hormonal factors. Harris J.R., Lippman M.E., Morrow M., Hellman S. Diseases of the Breast. 1996;185-200 Lippincott-Ravan Publishers, Philadelphia.
24. Tsongalis G.J., Linfert D.R., Johnson R.C. et al. Double heterozygosity for mutations in the BRCA1 and BRCA2 genes in a breast cancer patient. Arch. Pathol. Lab. Med. 122:1998;548-550.
25. Cummings S., Olopade O. Predisposition testing for inherited breast cancer. Oncology. 12(8):1998;1227-1242.
26. Miki Y., Swensen J., Shattuck-Eiden D. et al. A strong candidate gene for the breast and ovarian cancer susceptibility gene BRCA1. Science. 266:1994;66.
27. Wooster R., Bignell G., Lancaster J. et al. Identification of the breast cancer susceptibility gene BRCA2. Nature. 378:1995;789-792.
28. Newman B., Austin M.A., Lee M., King M.C. Inheritance of human breast cancer: evidence for autosomal dominant transmission in high-risk families. Proc. Natl. Acad. Sci. 85:1988;3044-3048.
29. Narod S.A., Reuteun J., Lynch H.T., Watson P., Conway T., Lynch J., Lenoir G.M. Familial breast-ovarian cancer locus on chromosome 17q12-q23. Lancet. 338:1991;82-83.
30. Akashi-Tanaka S., Fukutomi T., Tukami A., Fujiki T. Male breast cancer in patients with a familial history of breast cancer. Surg. Today. 26:1996;975-979.
31. Stratton M.R., Ford D., Neuhasen S., Seal S., Wooster R., Friedman L.S., King M.C., Egilsson V., Devilee P., McManus R. et al. Familial male breast cancer is not linked to the BRCA1 locus on chromosome 17q. Nat. Genet. 7:1994;103-107.
32. Burke W., Press N., Pinsky L. BRCA1 and BRCA2: a small part of the puzzle. J. Natl. Cancer Inst. 91(11):1999;904-905.
33. Claus E.B., Schildkraut J., Iversen E.S. Jr, Berry D., Parmigiani G. Effect of BRCA1 and BRCA2 on the association between breast cancer risk and family history. J. Natl. Cancer Inst. 90(23):1998;1824-1829.
34. Brody L.C., Biesecker B.B. Breast cancer susceptibility genes: BRCA1 and BRCA2. Rev. Mol. Med. 77(3):1998;208-226.
35. Struewing J.P., Hartge P., Wacholder S. et al. The risk of cancer associated with specific mutations of BRCA1 and BRCA2 among Ashkenazi Jews. N. Engl. J. Med. 336(20):1997;1401-1408.
36. Dupont W., Page D. Risk factors for breast cancer in women with proliferative breast disease. N. Engl. J. Med. 312:1985;146-151.
37. Dickson R.B. Biochemical control of breast development. Harris J.R., Lippman M.E., Morrow M., Hellman S. Diseases of the Breast. 1996;1525 Lippincott-Ravan Publishers, Philadelphia.
38. Dickson R.B., Lippman M.E. Oncogenes and suppressor genes. Harris J.R., Lippman M.E., Morrow M., Hellman S. Diseases of the Breast. 1996;221-235 Lippincott-Ravan Publishers, Philadelphia.
39. Evan G., Littlewood T. A matter of life and cell death (review). Science. 281:1998;1317-1322.
40. Lupulescu A.P. Hormones, vitamins and growth factors in cancer treatment and prevention. Cancer. 78(11):1996;2264-2280.
41. Dickson R., Lippman M.E. Growth factors in breast cancer. Endocr. Rev. 16:1995;559.
42. Slamon D.J., Clark G.M., Wong S.G., Levin W.J., Ullrich A., McGuire W.L. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science. 235(4785):1987;177-182.
43. Clark G.M., McGuire W.L. Follow-up study of HER-2/neu amplification in primary breast cancer. Cancer Res. 51:1991;944-948.
44. Liu E., Thor A., He Mei, Barcos M., Ljung B.-M., Benz C. The HER2 (c-erbB-2) oncogene is frequently amplified in situ carcinomas of the breast. Oncogene. 7:1992;1027-1032.
45. Carter P., Presta L., Gorman C.M., Ridgway J.B., Henner D., Wong W.L., Rowland A.M., Kotts C., Carver M., Shepard H.M. Humanization of anti-p185HER2 antibody for human cancer therapy. Proc. Natl. Acad. Sci. 89:1989;4285-4289.
46. HER2 monoclonal antibody has antiproliferative effects in vitro, and sensitizes human breast tumor cells to tumor necrosis factor. Mol. Cell Biol. 9:1989;1165-1172.
47. Gusterson B.A., Gelber R.D., Goldhirsch A., Price K.N., Save-Soderborgh J., Anbazhagan R., Styles J., Rudenstam C.M., Golouh R. et al. Prognostic importance of c-erbB-2 expression in breast cancer. J. Clin. Oncol. 10(7):1992;1049-1056.
48. Press M.F., Bernstein L., Thomas P.A., Meisner L.F., Zhou J.Y., Ma Y., Hung G., Robinson R.A., Harris C., El-Naggar A., Slamon D.J., Phillips R.N., Ross J.S., Wolman S.R., Flom K.J. HER-2/neu gene amplification characterized by fluorescence in situ hybridization: poor prognosis in node-negative breast carcinomas. J. Clin. Oncol. 15(8):1997;2894-2904.
49. Baselga K., Norton L., Albanell J., Kim Y.M., Mendelsohn J. Recombinant humanized anti-HER2 antibody (Herceptin TM) enhances the antitumor activity of paclitaxel and doxorubicin against Her2/neu overexpressing human breast cancer xenografts. Cancer Res. 58:1998;2825-2831.
50. De Bolos C., Guma M., Barranco C. et al. MUC6 expression in breast tissues and cultured cells: abnormal expression in tumors and regulation by steroid hormones. Int. J. Cancer. 77:1998;193-199.
51. Brockhausen I. Biosythesis and functions of 0-glycans and regulation of mucin antigen expression in cancer. Biochem. Soc. Trans. 25(3):1997;871-874.
52. Hiyama E., Gollahon L., Kataoka T. et al. Telomerase activity in human breast tumors. J. Natl. Cancer Inst. 88(2):1996;116-122.
53. Cuthbert A.P., Bond J., Trott D.A. et al. Telomerase repressor sequences on chromosome 3 and induction of permanent growth arrest in human breast cancer cells. J. Natl. Cancer Inst. 91(1):1999;37-45.
54. Adams J.M., Cory S. The Bcl-2 protein family: arbiters of cell survival. Science. 281:1998;1322-1326.
55. Kerr J.F.R., Winterford C.M., Harmon B.V. Apoptosis: its significance in cancer and cancer therapy. Cancer. 73:1994;2013-2026.
56. Krajewski S., Blomqvist C., Franssila K., Krajewska M., Wasenius V.-M., Niskanen E., Nordling S., Reed J.C. Reduced expression of proapoptotic gene BAX is associated with poor response rates to combination chemotherapy and shorter survival in women with metastatic breast adenocarcinoma. Cancer Res. 55:1995;4471-4478.
57. Dickson R.B., Lippman M.E. Ch 36: cancer of the breast. DeVita V.T., Hellman S., Rosenberg S.A. Cancer: Principles and Practice of Oncology. 5th ed:1997;1541-1557 Lippincott-Raven Publishers, Philadelphia.
58. Weinberg R.A. The retinoblastoma protein and cell cycle control. Cell. 81:1995;323-330.
59. Oyama T., Kashiwabara K., Yoshimoto K., Arnold A., Koerner F. Frequent overexpression of the cyclin D1 oncogene in invasive lobular carcinoma of the breast. Cancer Res. 58:1998;2876-2880.
60. Gedes J., Lemke H., Baisch H., Wacker H., Schwab U., Stein H. Cell cycle analysis of a cell proliferation-associated human nuclear antigen defined by the monoclonal antibody Ki-67. J. Immunol. 133:1984;1710-1715.
61. Rudolph P., Alm P., Heidebrecht H.-J. et al. Immunologic proliferation marker Ki-S2 a prognostic indicator for lymph node-negative breast cancer. J. Natl. Cancer Inst. 91(3):1999;271-278.
62. Jacquemier J.D., Penault-Llorca F.M., Bertucci F., Sun Z.Z., Houvenaeghel G.F., Geneix J.A., Guig B.D., Bardou V.J.H., Hassoun J.A., Birnbaum D., Viens P.J. Angiogenesis as a prognostic marker in breast carcinoma with conventional adjuvant chemotherapy: a multiparametric and immunohistochemical analysis. J. Pathol. 184:1998;130-135.
63. Weidner N., Semle J.P., Welch W.R., Folkman J. Tumor angiogenesis and metastasis - correlation in invasive breast carcinoma. N. Engl. J. Med. 324(1):1991;1-8.
64. Weidner N. Tumoural vascularity as a prognostic factor in cancer patients: the evidence continues to grow. J. Pathol. 184:1998;119-122.
65. Narita M., Nakao K., Ogino N., Nakagara M., Onishi A., Tsujimot M. Independent prognostic factors in breast cancer patients. Am. J. Surg. 175(1):1998;73-75.
66. Nicosia R.F. Commentary: what is the role of vascular endothelial growth factor related molecules in tumor angiogenesis. Am. J. Pathol. 153(1):1998;11-16.
67. Ferrara N., Davis-Smyth T. The biology of vascular endothelial growth factor. Endocrinol. Rev. 18:1997;4-25.
68. Kieser A., Weich H., Brandner G., Marme D., Kolch W. Mutant p53 potentiates protein kinase C induction of vascular endothelial growth factor expression. Oncogene. 9:1994;963-969.
69. Walton T., Wang J.L., Ribas A., Barsky S.H., Economou J., Nguyen M. Endothelium-specific expression of an e-Selectin promoter recombinant adenoviral vector. Anticancer Res. 18:1998;1357-1360.
70. Atkins K.B., Troen B.R. Regulation of cathepsin D gene expression in HL-60 cells by retinoic acid and calcitriol. Cell Growth Differ. 6:1995;871-877.
71. Alford D., Pitha-Rowe P., Taylor-Papadimitriou J. Adhesion molecules in breast cancer: role of alpha 2 beta 1 integrin. Biochem. Soc. Symp. 63:1998;245-259.
72. Lee S.W., Reimer C.L., Campbell D.B., Cheresh P., Duda R.B., Kocher O. H-cadherin expression inhibits in vitro invasiveness and tumor formation in vivo. Carcinogenesis. 19(6):1998;1157-1159.
73. Beyer E.C., Paul D.A. Topical review: connexin family of gap junction proteins. J. Membr. Biol. 116:1990;187-194.
74. Wilgenbus K.K., Kirkpatrick C.J., Knuechel R., Willecke K., Traub O. Expression of Cx26, Cx32, and Cx43 gap junction proteins in normal and neoplastic human tissues. Int. J. Cancer. 51(4):1992;522-529.
75. Lee S.W., Tomasetto C., Paul D., Keyomarsi K., Sager R. Transcriptional downregulation of gap-junction proteins blocks junctional communication in human mammary tumor cell lines. J. Cell. Biol. 118(5):1992;1213-1221.
76. Jamieson S., Going J.J., D'Arcy R., George W.D. Expression of gap junction proteins connexin 26 and connexin 43 in normal human breast and in breast tumours. J. Pathol. 184(1):1998;37-43.
77. Li G.Y., Lin H.H., Tu Z.J., Kiang D.T. Cap junction Cx26 gene modulation by phorbol esters in benign and malignant human mammary cells. Gene. 209:1998;139-147.
78. Decensi A., Formilli F., Torrisi R., Costa A. Breast cancer chemoprevention: studies with 4-HPR alone and in combination with tamoxifen using circulating growth factors as potential surrogate endpoints. J. Cell. Biochem. 17G:1993;226-233.
79. Baak J.P.A., Diest P.J., Benraadt T., Matze-Cok E., Brugghe J., Schuurmans L.T., Littooy J.J. et al. The mult-center morphometric mammary carcinoma project (MMMCP) in the Netherlands: value of morphometrically assessed proliferation and differentiation. J. Cell. Biochem. 17G:1993;220-225.
80. Steele V.E., Boone C.W., Lubet R.A., Crowell J.A., Holmes C.A., Sigman C.C., Kelloff G.J. Preclinical drug development paradigms for chemopreventives. Hematol. Oncol. Clin. North Am. 12(5):1998;943-961.
81. Gullino P., Pettigrew H.M., Grantham F.H. N-Nitrosomethylurea as mammary gland carcinogen in rats. J. Natl. Cancer Inst. 54:1975;401-414.
82. Clark R. Animal models of breast cancer: their diversity and role in biomedical research. Breast Cancer Res. Treat. 39:1996;1-6.
83. Clark R. Animal models of breast cancer: experimental design and their use in nutrition and psychosocial research. Breast Cancer Res. Treat. 47:1997;117-133.
84. Moon R.C., Mehta R.G. Chemoprevention of experimental carcinogenesis in animals. Prev. Med. 18:1989;576-591.
85. Greenwald P. Preventive clinical trials: an overview. Ann. NY Acad. Sci. 768:1995;129-140.
86. Dunn B.K., Kramer B.S., Ford L.G. Phase III, large-scale chemoprevention trials. Approach to chemoprevention clinical trials and phase III clinical trial of tamoxifen as a chemopreventive for breast cancer - the US National Cancer Institute experience. Hematol. Oncol. Clin. North Am. 12(5):1998;1019-1036.
87. Harper M.J.K., Walpole A.L. A new derivative of triphenylethlene: effect on implantation and mode of action in rats. J. Reprod. Fertil. 13:1967;101-119.
88. Jordan V.C. Chemosuppression of breast cancer with tamoxifen - laboratory evidence and future clinical investigation. Cancer Invest. 6:1988;589-595.
89. Fisher B., Costantino J.P., Wickerham D.L., Redmond C.K., Kavanah M., Cronin W.M. et al. Tamoxifen for prevention of breast cancer: report of the national surgical adjuvant breast and bowel project P-1 study. J. Natl. Cancer Inst. 90:1998;1371-1388.
90. Powles T.J. Status of antiestrogen breast cancer prevention trials. Oncology. 12(Suppl. 5):1998;28-31.
91. Manni A. Clinical use of aromatase inhibitors in the treatment of breast cancers. J. Cell. Biochem. 17G:1993;242-246.
92. Inada K., Tominaga T., Toi M., Yamamoto Y., Abe M., Yamashita J., Ogawa M. Protective effect on 7,12-dimethylbenz(a)anthracene (DMBA)-induced mammary carcinogenesis in rats. Eur. J. Surg. Oncol. 22:1996;583-587.
93. Torrisi R., Pensa F., Orengo M.A. et al. The synthetic retinoid fenretinide lowers plasma insulin-like growth factor I levels in breast cancer patients. Cancer Res. 53:1993;4769-4771.
94. Zhou Q., Stetler-Stevenson M., Steeg P. Inhibition of cyclin D expression in human breast carcinoma cells by retinoids in vitro. Oncogene. 15(1):1997;107-115.
95. Kelloff G.J., Boone C.W., Steele V.E., Crowell J.A., Lubet R., Doody L.A., Greenwald P. Development of breast cancer chemopreventive drugs. J. Cell. Biochem. 17G:1993;2-13.
96. Toma S., Isnardi L., Raffo P., Dastoli G., De Francisci E., Riccardi L., Palumbo R., Bollag W. Effects of all-trans-retinoic acid and 13-cis-retinoic acid on breast-cancer cell lines: growth inhibition and apoptosis induction. Int. J. Cancer. 70:1997;619-627.
97. Rock C.L. Nutritional factors in cancer prevention. Hematol. Oncol. Clin. North Am. 12(5):1998;975-991.
98. De Palo G., Camerini T., Marubini E., Costa A., Formelli F., Del Vecchio M., Mariani L. et al. Chemoprevention trial of contralateral breast cancer with fenretinide. Rationale, design, methodology, organization, data management, statistics and accrual. Tumori. 83(6):1997;884-894.
99. Seewaldt V.L., Kim J.-H., Caldwell L.E., Jahnson B.S., Swisshelm K., Collins S.J. All-trans-retinoic acid mediates G1 arrest but not apoptosis of normal human mammary epithelial cells. Cell Growth Differ. 8:1997;631-641.
100. O'Shaughnessy J.A. Chemoprevention of breast cancer. J. Am. Med. Assoc. 275(17):1996;1349-1353.
101. Omenn G.S., Goodman G.E., Thornquist M.D., Balmes J., Cullen M.F., Glass A., Keogh J.P. et al. Effects of a combination of beta-carotene and vitamin A on lung cancer and cardiovascular disease. N. Engl. J. Med. 334(18):1996;1150-1155.
102. Zhang S., Hunter D.J., Forman M.F. et al. Dietary carotenoids and vitamins A, C, and E and risk of breast cancer. J. Natl. Cancer Inst. 91(6):1999;547-556.
103. Wong G.Y., Bradlow L., Sepkovic D., Mehl S., Mailman J., Osborne M.P. Dose-ranging study of indole-3-carbinol for breast cancer prevention. J. Cell. Biochem. S28, 29:1997;111-116.
104. Schut H.A., Dashwood R.H. Inhibition of DNA adduct formation of 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine (PhIP) by dietary indole-3-carbinol (I3C) in the mammary gland, colon, and liver of the female F-344 rat. Ann. NY Acad. Sci. 768:1995;210-214.
105. Bradlow H.L., Sepkovic D.W., Telang N.T., Osborne M.P. Indole-3-carbinol: a novel approach to breast cancer prevention. Ann. NY Acad. Sci. 768:1995;180-200.
106. Wattenberg L.W., Loub W.D. Inhibition of polycyclic aromatic hydrocarbon induced neoplasia by naturally occurring indoles. Cancer Res. 38:1978;1410-1413.
107. Ursin G., London S., Stanczyk F.Z. et al. Urinary 2-Hydroxyestrone/16α-Hydroxyestrone ratio and risk of breast cancer in postmenopauseal women. J. Natl. Cancer Inst. 91(12):1999;1067-1072.
108. Telang N.T., Katdare M., Bradlow H.L., Osborne M.P., Fishman J. Inhibition of proliferation and modulation of estradiol metabolism: novel mechanisms for breast cancer prevention by the phytochemical indole-3-carbinol. Proc. Soc. Exp. Biol. Med. 216(2):1997;246-252.
109. Walz E. Isoflavon- and saponin-glucoside. Soja Hispida Justus Liebigs Ann. Chem. 498:1931;118-155. in German.
110. Walter E.D. Genistin (an isoflavone glucoside) and its aglucone, genistein, from soybeans. J. Am. Chem. Soc. 63:1941;3273-3276.
111. Liang Y.-C., Chen Y.-C., Lin Y.-L., Lin-Shiau S.-Y., Ho C.-T., Lin J.-K. Suppression of extracellular signals and cell proliferation by the black tea polyphenyl, theaflavin-3,3′-digallate. Carcinogenesis. 20(4):1999;733-736.
112. Araki R., Inoue S., Osborne M.P., Telang N.T. Chemoprevention of mammary preneoplasia: in vitro effects of green tea polyphenol. Ann. NY Acad. Sci. 768:1995;215-222.
113. Wang C., Makela T., Hase T., Adlercreutz H., Kurzer M.S. Lignans and isoflavonoids inhibit aromatase enzyme in human preadipocytes. J. Steroid. Biochem. Mol. Biol. 50(3, 4):1994;205-212.
114. Makela S., Poutanen M., Lehtimaki J., Kostian M.L., Santti R., Vihko R. Estrogen-specific 17β-hydroxysteroid oxidoreductase Type I as a possible target for the action of phytoestrogens. Proc. Soc. Exp. Biol. Med. 208:1995;51-59.
115. Zava D.T., Dollbaum C.M., Blen M. Estrogen and progestin bioactivity of foods, herbs, and spices. Proc. Soc. Exp. Biol. Med. 217:1998;369-378.
116. Barnes S. The chemopreventive properties of soy isoflavonoids in animal models of breast cancer. Breast Cancer Res. Treat. 46:1997;169-179.
117. Crowell P.L. Monoterpenes in breast cancer chemoprevention. Breast Cancer Res. Treat. 46(2, 3):1997;191-197.
118. Jirtle R., Haag J.D., Ariazi E.A. et al. Increased mannose 6-phosphate/insulin-like growth factor II receptor and transforming growth factor beta 1 levels during monoterpene-induced regression of mammary tumors. Cancer Res. 53:1993;3849-3852.
119. Mills J.J., Chari R.S., Boyer I.J., Gould M.N., Hirtle R.L. Induction of apoptosis in liver tumors by the monoterpene perillyl alcohol. Cancer Res. 55:1995;979-983.
120. 1 levels contributing to an early G1 arrest in mammary cells. Proc. Am. Assoc. Cancer Res. 38:1997;263.
121. Ren Z., Gould M.N. Modulation of small G protein isoprenylation by anticancer monoterpenes in in situ mammary gland epithelial cells. Carcinogenesis. 19(5):1998;827-832.
122. Crowell P.L., Chang R.R., Ren Z., Elson C.E., Gould M.N. Selective inhibition of isoprenylation of 21-26 kDa proteins by the anticarcinogen D-limonene and its metabolites. J. Biol. Chem. 266:1994;17679-17685.
123. Gould M.N. Prevention and therapy of mammary cancer by monoterpenes. J. Cell. Biochem. 22:1995;139-144.
124. Ripple G.H., Gould M.N., Stewart J.A., Tutsch K.D., Arzoomanian R.Z., Alberti D., Feierabend C., Pomplun M., Wilding G., Bailey H.H. Phase I clinical trial of perillyl alcohol administered daily. Clin. Cancer Res. 4:1998;1159-1164.
125. El-Bayoumy K., Upadhyaya P., Chae Y.H., Sohn O.S., Rao C.V., Fiala I., Reddy B.S. Chemoprevention of cancer by organoselenium. J. Cell. Biochem. 22:1995;92-100.
126. Clement I.P., Thompson H.J., Ganther H.E. Cytostasis and cancer chemoprevention: investigating the action of triphenylselenonium chloride in in vivo models of mammary carcinogenesis. Anticancer Res. 18:1998;9-12.
127. 5. J. Natl. Cancer Inst. 89(3):1997;212-218.
128. 3 and its analogues. J. Biol. Chem. 273(13):1998;7749-7756.
129. Chan T.A., Morin P.J., Vogelstein B., Kinzler K.W. Mechanisms underlying nonsteroidal antiinflammatory drug-mediated apoptosis. Proc. Natl. Acad. Sci. 95:1998;681-686.
130. Ohshima H., Bartsch H. Chronic infections and inflammatory processes as cancer risk factors: possible role of nitric oxide in carcinogenesis. Mutat. Res. 305:1994;253-264.
131. Gao X., Hagmann W., Zacharek A., Wu N., Lee M., Porter A.T., Honn K.V. Eicosanoids, cancer metastasis and gene regulation: an overview. Honn K.V. et al. Eicosanoids and Other Bioactive Lipids in Cancer, Inflammation and Radiation Injury 2. 1997;545-555 Plenum Press, New York.
132. Morecki S., Yacovlev L., Slavin S. Effect of indomethacin on tumorgenicity and immunity induction in a murine model of mammary carcinoma. Int. J. Cancer. 75(6):1998;894-899.
133. Robertson F.M., Parrett M.L., Joarder F.S., Ross M., Abou-Issa H.M., Alshafie F., Harris R.E. Ibuprofen-induced inhibition of cyclooxygenase isoform gene expression and regression of rat mammary carcinomas. Cancer Lett. 122(1-2):1998;165-175.
134. Vainio H., Morgan G. Cyclo-oxygenase 2 and breast cancer prevention: non-steroidal anti-inflammatory agents are worth testing in breast cancer. Br. Med. J. 317(7162):1998;828.
135. Parrett M.L., Harris R.E., Joarder F.S., Ross M.S., Clausen K.P., Robertson F.M. Cyclooxygenase-2 gene expression in human breast cancer. Int. J. Oncol. 10:1997;503-507.
136. Suh N., Wang Y., Honda T. et al. A novel synthetic oleanane triterpenoid, 2-cyano-3,12-dioxoolean-1,9-dien-28-oic acid, with potent differentiating, antiproliferative, and anti-inflammatory activity. Cancer Res. 59:1999;336-341.
137. Suh N., Honda T., Finlay H.J. et al. Novel triterpenoids suppress inducible nitric oxide synthase (iNOS) and inducible cyclooxygenase (COX-2) in mouse macrophages. Cancer Res. 58:1998;717-723.
138. Noguchi M., Rose D.P., Miyazaki I. Breast cancer chemoprevention: clinical trials and research. Oncology. 53:1996;175-181.
139. Noguchi M., Minami M., Yagasaki R., Kinoshita K., Earashi M., Kitagawa H., Taniya T., Miyazaki I. Chemoprevention of DMBA-induced mammary carcinogenesis in rats by low-dose EPA and DHA. Br. J. Cancer. 75(3):1997;348-353.
140. Deshpande S.S., Ingle A.D., Maru G.B. Chemopreventive efficacy of curcumin-free aqueous turmeric extract in 7,12-demethylbenz[a]anthracene-induced rat mammary tumorigenesis. Cancer Lett. 123:1998;35-40.
141. Heerdt A.S., Young C.W., Borgen P.I. Calcium glucarate as a chemopreventive agent in breast cancer. Isr. J. Med. Sci. 31:1995;101-105.
142. Jang M., Cai L., Udeani G.O., Slowing K.V., Thomas C.F., Beecher C.W.W., Fong H.H.S., Rarnsworth N.R., Knighorn A.D., Mehta R.G., Moon R.C., Pezzuto J.M. Cancer chemopreventive activity of Resveratrol, a natural product derived from grapes. Science. 275(5297):1997;218-220.
143. 2 phase. Biochem. Biophys. Res. Commun. 250(1):1998;53-58.
144. Bertelli A.A., Giovannini L., Stradi R., Urien S., Tillement J.P., Bertelli A. Evaluation of kinetic parameters of natural phytoalexin in resveratrol orally administered in wine to rats. Drugs Exp. Clin. Res. 24(1):1998;51-55.
145. Ervin P.R. Jr, Kaminski M.S., Cody R.L., Wicha M.S. Production of mammastatin, a tissue-specific growth inhibitor, by normal human mammary cells. Science. 244:1989;1585-1587.
146. Barrie R., Woltering E.A., Hajarizadeh H., Mueller C., Ure T., Fletcher W.S. Inhibition of angiogenesis by somatostatin and somatostatin-like compounds is structurally dependent. J. Surg. Res. 55(4):1993;446-450.
147. Huynh H., Beamer W. Suppression of mammary-derived growth inhibitor gene expression by growth hormone and insulin-like growth factor I. Int. J. Oncol. 13(3):1998;577-582.
148. Costa A., De Palo G., Decensi A., Formelli R., Chiesa F., Nava M., Camerini T., Marubini E., Veronesi U. Retinoids in cancer chemoprevention: clinical trials with the synthetic analogue fenretinide. Ann. NY Acad. Sci. 768:1995;148-162.
149. Hennekens C.H., Buring J.E., Peto R. Antioxidant vitamins, cancer and cardiovascular disease. N. Engl. J. Med. 335(14):1996;1065-1069.
150. Osborne C.K. Drug therapy: tamoxifen in the treatment of breast cancer. N. Engl. J. Med. 339(22):1998;1609-1618.
151. Tamoxifen for early breast cancer: an overview of the randomised trials. Lancet. 351(9114):1998;1451-1467.
152. Powles T., Eeles R., Ashley S., Easton D., Chang J., Dowsett M., Tidy A., Viggers J., Davey J. Interim analysis of the incidence of breast cancer in the Royal Marsden Hospital tamoxifen randomized chemoprevention trial. Lancet. 352(9122):1998;98-101.
153. Veronesi U., Maisonneuve P., Costa A., Sacchini V., Maltoni C., Robertson C., Rotmensz N., Boyle P. Prevention of breast cancer with tamoxifen: preliminary findings from the Italian randomized trial among hysterectomised women. Lancet. 352(9122):1998;93-97.
154. DePalo G., Formelli F. Risks and benefits of retinoids in the chemoprevention of cancer. Drug Saf. 13(4):1995;245-256.
155. R (HPR). Eur. J. Cancer. Clin. Oncol. 25(5):1989;805-808.
156. Harvey H.A. Emerging role of aromatase inhibitors in the treatment of breast cancer. Oncology. 12(3):1998;32-35.
157. Henderson B.E., Ross R.K., Pike M.C. Toward the primary prevention of cancer. Science. 254:1991;1131-1138.
158. Helsenbeck S.G., Clark G.M. Surrogate endpoints in chemoprevention of breast cancer: guidelines for evaluation of new biomarkers. J. Cell. Biochem. 17G:1993;205-211.
159. Lippman S.M., Lee J.J., Sabichi A.L. Cancer chemoprevention: progress and promise. J. Natl. Cancer Inst. 90(20):1998;1514-1528.
160. Hartman L.C., Schaid D.J., Woods J.E., Crotty T.P., Myers J.L., Arnold P.G. et al. Efficacy of bilateral prophylactic mastectomy in women with a family history of breast cancer. N. Engl. J. Med. 340(2):1999;77-84.
161. Eisen A., Wever B.L. Prophylatic mastectomy - the price of fear. N. Engl. J. Med. 340(2):1999;137-138.
162. Brann V.R., Panageas K.S., Whang W., Antman K.H., Neugut A.I. Decision analysis of prophylactic mastectomy and oophorectomy in BRCA1-positive or BRCA2-positive patients. J. Clin. Oncol. 16(3):1998;979-985.